Significant Leverage Increase: Company assuming $500M in new debt with $24M additional annual interest expense, materially altering capital structure and increasing financial risk profile Acquisition-Driven Financing Risk: Debt proceeds dedicated to SomaLogic acquisition creates exposure to M&A execution and integration risks, with fixed debt obligations regardless of deal success Near-Term…

Our analysis rates this filing CAUTIOUS. The elevated concern level reflects a company undergoing significant capital structure changes that increase financial risk. The $500M debt issuance materially increases leverage and fixed obligations, while the allocation of proceeds to a proposed…

Concern level: HIGH (6.5/10). Key factors: Material increase in debt burden with $500M new issuance adding $23.75M in annual interest expense, reducing financial flexibility; Acquisition financing risk with proceeds earmarked for proposed SomaLogic transaction that has not yet closed, creating execution uncertainty; Near-term refinancing pressure with existing 5.800% notes maturing December 12,…

Notable risk changes: Company taking on $500M in new debt obligations, increasing annual interest expense by approximately $24M and overall leverage - represents material change to capital structure; Debt proceeds allocated to fund proposed SomaLogic acquisition introduces M&A execution risk and integration uncertainty while debt obligations remain fixed regardless of deal outcome; Imminent debt maturity (December…

The model predicts ILMN will outperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.